Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
German Centre for Infection Research, HepNet Study-House of the German Liver Foundation, Hannover, Germany.
JAMA Netw Open. 2023 Jul 3;6(7):e2322048. doi: 10.1001/jamanetworkopen.2023.22048.
The potential association of low-volume paracentesis of less than 5 L with complications in patients with ascites remains unclear, and individuals with cirrhosis and refractory ascites (RA) treated with devices like Alfapump or tunneled-intraperitoneal catheters perform daily low-volume drainage without albumin substitution. Studies indicate marked differences regarding the daily drainage volume between patients; however, it is currently unknown if this alters the clinical course.
To determine whether the incidence of complications, such as hyponatremia or acute kidney injury (AKI), is associated with the daily drainage volume in patients with devices.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of patients with liver cirrhosis, RA, and a contraindication for a transjugular intrahepatic portosystemic shunt who received either device implantation or standard of care (SOC; ie, repeated large-volume paracentesis with albumin infusion), and were hospitalized between 2012 and 2020 were included. Data were analyzed from April to October 2022.
Daily ascites volume removed.
The primary end points were 90-day incidence of hyponatremia and AKI. Propensity score matching was performed to match and compare patients with devices and higher or lower drainage volumes to those who received SOC.
Overall, 250 patients with RA receiving either device implantation (179 [72%] patients; 125 [70%] male; 54 [30%] female; mean [SD] age, 59 [11] years) or SOC (71 [28%] patients; 41 [67%] male; 20 [33%] female; mean [SD] age, 54 [8]) were included in this study. A cutoff of 1.5 L/d or more was identified to estimate hyponatremia and AKI in the included patients with devices. Drainage of 1.5 L/d or more was associated with hyponatremia and AKI, even after adjusting for various confounders (hazard ratio [HR], 2.17 [95% CI, 1.24-3.78]; P = .006; HR, 1.43 [95% CI, 1.01-2.16]; P = .04, respectively). Moreover, patients with taps of 1.5 L/d or more and less than 1.5 L/d were matched with patients receiving SOC. Those with taps of 1.5 L/d or more had a higher risk of hyponatremia and AKI compared with those receiving SOC (HR, 1.67 [95% CI, 1.06-2.68]; P = .02 and HR, 1.51 [95% CI, 1.04-2.18]; P = .03), while patients with drainage of less than 1.5 L/d did not show an increased rate of complications compared with those receiving SOC.
In this cohort study, clinical complications in patients with RA performing low-volume drainage without albumin infusion were associated with the daily volume drained. Based on this analysis, physicians should be cautious in patients performing drainage of 1.5 L/d or more without albumin infusion.
对于腹水患者,小容量腹腔穿刺术(小于 5 L)与并发症之间的潜在关联仍不清楚,而且接受 Alfapump 或隧道式腹腔内导管等设备治疗的肝硬化和难治性腹水(RA)患者每天进行小容量引流,而无需白蛋白替代。研究表明,患者之间的每日引流量存在明显差异;然而,目前尚不清楚这是否会改变临床病程。
确定在接受设备治疗的患者中,并发症(如低钠血症或急性肾损伤(AKI))的发生率是否与每日引流量有关。
设计、设置和参与者:这是一项回顾性队列研究,纳入了 2012 年至 2020 年期间接受过设备植入或标准治疗(即重复大体积腹腔穿刺术加白蛋白输注)的患有肝硬化、RA 且存在经颈静脉肝内门体分流术禁忌证的患者。数据于 2022 年 4 月至 10 月进行分析。
每天去除的腹水体积。
主要终点是 90 天内低钠血症和 AKI 的发生率。进行了倾向评分匹配,以比较接受设备治疗且引流体积较高或较低的患者与接受 SOC 治疗的患者。
本研究共纳入 250 例接受 RA 治疗的患者,其中 179 例(72%)患者接受设备植入(125 例[70%]为男性;54 例[30%]为女性;平均[SD]年龄为 59[11]岁),71 例(28%)患者接受 SOC(41 例[67%]为男性;20 例[33%]为女性;平均[SD]年龄为 54[8]岁)。确定了每天 1.5 L 或更多的引流来估计接受设备治疗的患者中低钠血症和 AKI 的发生情况。每天引流 1.5 L 或更多与低钠血症和 AKI 相关,即使在调整了各种混杂因素后(风险比[HR],2.17[95%CI,1.24-3.78];P=0.006;HR,1.43[95%CI,1.01-2.16];P=0.04)。此外,每天引流 1.5 L 或更多和小于 1.5 L 的患者与接受 SOC 的患者相匹配。与接受 SOC 的患者相比,每天引流 1.5 L 或更多的患者发生低钠血症和 AKI 的风险更高(HR,1.67[95%CI,1.06-2.68];P=0.02 和 HR,1.51[95%CI,1.04-2.18];P=0.03),而每天引流小于 1.5 L 的患者与接受 SOC 的患者相比,并发症发生率没有增加。
在这项队列研究中,接受无白蛋白输注的小容量引流的 RA 患者发生临床并发症与每日引流量有关。基于这一分析,医生在对每天引流 1.5 L 或更多而不使用白蛋白的患者进行治疗时应谨慎。